News & Events

In this section

Simbec Research Selects ALPHADAS to Streamline Clinical Trial Processes

ALPHADAS Chosen by one of Europe’s Leading and Longest Established Early Phase Contract Research Organizations

CONSHOHOCKEN, PA - (BUSINESS WIRE) – February 13, 2014 - - Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that Simbec Research (“Simbec”) has purchased the ALPHADAS® clinical trials software solution suite for deployment in its UK-based Phase I unit.

Founded in 1976, Simbec is one of Europe’s leading contract research organizations specializing in early clinical research services for the international pharmaceutical industry. Simbec has conducted over 1,500 early phase clinical studies; created, planned and managed within a wide range of therapeutic areas.

In addition to its comprehensive functionality, Simbec selected Instem’s ALPHADAS software suite due to its proven reputation for quality and performance among the world’s leading research organizations. ALPHADAS is the standard for early phase systems used by organizations across four continents to improve client efficiencies, reduce trial times and provide real-time data to sponsors.

“Part of Simbec’s market evaluation was a month long trial versus another system which gave them the focused testing environment to fully compare the systems” comments Mark Cusack, VP Business Development at Instem Clinical. “ALPHADAS being favoured in this competitive comparison was further supported by our peerless track record of delivery and success.  The fact that ALPHADAS can be deployed ‘out of the box’ to meet Simbec’s requirements coupled with the significant additional value to their clients means ALPHADAS will deliver an immediate return on investment for Simbec, and prove a clear competitive distinction.”

Simbec has been experiencing strong growth and now supported by the investment from the newly created £100m WLSIF fund, which is managed by Professor Sir Christopher Evans’ Arthurian, Simbec’s selection of ALPHADAS and the global Instem organization is a strong and highly visible endorsement.

Instem’s ALPHADAS software solution suite is a proactive eSource clinical research and early phase trials system that is mobile, schedule-driven, and provides real-time bedside or station based direct data capture that virtually eliminates paper-based data.

“We are looking forward to establishing a long term partnership with Instem, and knowing how closely they collaborate with clients gives us the confidence that ALPHADAS will help us deliver the next level of research excellence and uncompromised standards of quality,” states Dr. Trevor Tanner, Director of Scientific Affairs at Simbec.

Key Facts

  • ALPHADAS to be deployed at Simbec, a leading UK Phase I unit
  • ALPHADAS software suite replacing legacy system
  • Simbec to implement ALPHADAS CTMS and Sample Tracking during first stage of project
  • Instem chosen for global market leadership, stability and reputation

About Simbec Research

Founded in 1976 with a small team of researchers from the UK National Health Service, Simbec Research is now one of Europe’s leading contract research organizations specializing in early clinical research services for the international pharmaceutical industry. Simbec has a stellar track record for safety and compliance in Phase I/IIa project delivery to the pharmaceutical and biotechnology industries. Simbec additionally provides a wide range of services for bioequivalence studies and its
Central Laboratory Service, with fully GLP and GCP compliant laboratories, is accredited by the CPA (UK).

More about Simbec can be found at www.simbec.com

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

Meeting clients at the intersection of investment & return™.

Press Contacts:

Instem
Gary Mitchell (US HQ)
gary.mitchell@instem.com
Tel: 610-941-0990

Julie Jones (UK HQ)
julie.jones@instem.com
Tel: +44 (0) 1785 825600